ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Esmolol Hydrochloride Double Strength In Plastic Container, and when can generic versions of Esmolol Hydrochloride Double Strength In Plastic Container launch?

Esmolol Hydrochloride Double Strength In Plastic Container is a drug marketed by Hq Spclt Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has seven patent family members in seven countries.

The generic ingredient in ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER is esmolol hydrochloride. There are eight drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Esmolol Hydrochloride Double Strength In Plastic Container

A generic version of ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER was approved as esmolol hydrochloride by HIKMA on August 10^th, 2004.

Summary for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

International Patents:	7
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	130
Patent Applications:	806
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER
DailyMed Link:	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Western University, Canada	PHASE1
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	PHASE1
John Basmaji	PHASE1

See all ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER clinical trials

Pharmacology for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-002	Apr 7, 2016		RX	Yes	Yes	8,835,505		Y
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-002	Apr 7, 2016		RX	Yes	Yes	8,829,054		Y

International Patents for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

See the table below for patents covering ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Slovakia	288113
Japan	2004519506
Canada	2906031	COMPOSITION PHARMACEUTIQUE DE COSOLVANTS PRETE A L'UTILISATION DANS DES RECIPIENTS DE MATIERE PLASTIQUE FLEXIBLES MODIFIES (READY-TO-USE CO-SOLVENTS PHARMACEUTICAL COMPOSITION IN MODIFIED FLEXIBLE PLASTIC CONTAINER)
Slovenia	1368019
Austria	341319

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is the product’s market footprint and how does it sell?

EsmoLOL HYDROCHLORIDE “double strength” in a plastic container is an intravenous beta-adrenergic blocker used in acute cardiovascular settings, where clinicians titrate dosing by infusion rate. The label construct (double-strength concentration and plastic container format) is designed for practical administration and consistent dosing during hospital use.

Core demand drivers

• Hospital-driven, acute care use: Market pull comes from inpatient settings that manage tachyarrhythmias, peri-operative cardiac management, and similar acute indications. Procurement cycles follow hospital formularies and standard-of-care protocols, not consumer demand.
• Titration workflow: Esmolol’s “short-acting” IV profile supports rapid titration. That clinical fit translates into recurring demand for infusion-ready preparations.

Commercial implications of “double strength” and container

• Concentration strategy: Double strength can reduce infusion volume requirements at a given mg dose, which reduces handling time and fluid load in some clinical workflows.
• Plastic container value: Plastic containers are typically preferred for dose accuracy, handling, and compatibility with IV administration practices versus older glass formats (where applicable).

How competitive is this market and what determines pricing power?

The esmolol IV segment is shaped by (1) generic competition after originator exclusivity, and (2) substitution at the point of care when hospital pharmacy policies permit.

Key competitive forces

• Generic erosion risk: IV specialty generics typically experience price compression after approval and formulary adoption, especially when multiple AB-rated products exist.
• Formulary switching friction: Hospitals often rationalize procurement around a small number of contracted suppliers, so price is negotiated aggressively once multiple options are available.
• Container and concentration constraints: If the originator’s specific concentration/container format is replicated by approved generics, switching accelerates. If it is not, the incumbent can retain partial pricing power through operational fit.

What do adoption and procurement cycles look like?

Typical cycle

• Hospital Pharmacy and Therapeutics committees update formularies on a periodic cadence and during bid cycles.
• IV products are often evaluated based on contract price, availability, stability, and supply reliability.

Procurement levers

• Tender and contract pricing dominate near-term unit economics.
• Inventory and supply continuity influence reorder cadence during tender execution.
• Clinical substitution policy determines whether pharmacists can switch to equivalent concentration and container without administrative delays.

What regulatory and IP milestones govern the product trajectory?

Financial trajectory in this segment hinges on the date structure of market exclusivity, patent status, and generic entry.

How patent life translates into revenue shape

For IV small-molecule generics, the revenue curve typically follows:

1. Exclusivity window: Higher margin pricing at launch or post-authorization period.
2. Entry of competition: Margin compression as generics enter and secure formulary access.
3. Consolidation: Contracts lock-in lower prices; incremental revenue becomes volume-driven.
4. Periodic re-bidding: Further downward pressure when existing contracts expire.

Where “double strength” affects IP and entry

A “double strength” presentation can still face competition from:

• Generics that match the concentration and container type, enabling direct substitution; or
• Therapeutic alternatives with similar clinical use but different formulation or dosing scheme, limiting substitution if dosing workflows differ.

What financial trajectory is consistent with IV beta-blocker competition?

Without product-specific financial disclosures provided here, the only defensible financial pattern is the sector-standard lifecycle for an IV generic-facing beta-blocker presentation.

Expected revenue and margin path (market-structure driven)

• Early period (if recently launched or converted): Revenue is stable if hospitals adopt quickly into formulary and contracts secure steady supply.
• Mid period (post-generic entry by peers): Revenue growth slows; price per unit compresses. Volume may hold or decline slowly depending on competitor placement.
• Late period (contract-driven mature phase): Revenue becomes a function of contracted volume and substitution rates; margins compress further, with operating profitability sustained via scale, procurement efficiency, and logistics.

Cost structure and why it matters

• Inventory and distribution: IV products require reliable cold-chain or stability management depending on label storage. Contracting reduces unit costs but increases service obligations.
• Manufacturing yields and QA: Unit manufacturing cost drives gross margin more than marketing spend.
• Regulatory/quality spend: Bioanalytical and stability programs increase fixed costs; mature periods benefit from amortization but still face inspection-related capex.

How does payer behavior affect near-term economics?

IV acute-care drugs are typically reimbursed under inpatient procurement and billing structures. Payer dynamics matter indirectly through hospital budget constraints and formulary pressure.

What changes the price outcome

• DRG and inpatient payment frameworks encourage hospitals to minimize drug spend, increasing pressure on drug manufacturers to cut net prices through contracting.
• Utilization review: Hospitals that reduce length of stay or protocolize titration can change unit consumption rates.

What is the most likely demand volatility profile?

The esmolol use case is acute, so demand is sensitive to:

• Case mix changes (seasonal trends in cardiovascular presentations can shift hospital utilization slightly).
• Protocol adoption: If guideline-based titration protocols standardize esmolol use, demand becomes more predictable.
• Supply availability: Shortages in IV beta-blockers can create “temporary preference” purchasing behaviors, followed by normalization once supply stabilizes.

How do product presentation and supply strategy change the revenue curve?

A “double strength in plastic container” presentation can influence both share and net price.

Presentation advantages that drive volume

• Lower infusion volume can help when fluid restriction matters.
• Dose preparation simplification can reduce bedside preparation time and staff handling errors.

Presentation constraints that limit upside

• If competitors offer equivalent concentration but with different stability or container handling characteristics, the hospital may choose based on contract rather than clinical preference.

Supply strategy

• Stable supply supports contract retention; missed deliveries lead to exclusion and short-term volume loss even if list price is competitive.

What are the likely sales channels and contract structures?

• Direct hospital distribution under procurement agreements is the dominant path for IV drugs.
• Group purchasing organizations (GPOs) often set benchmarks for pricing and can speed adoption of low-cost entrants.
• Wholesaler secondary distribution depends on contract terms and allocation during demand spikes.

Key risks to the financial trajectory

1. Price compression from generic substitution as additional AB-rated offerings gain formulary access.
2. Contract renegotiation risk at rebid points, which can lower net price quickly.
3. Supply risk (manufacturing interruption) because IV hospital purchasing punishes stock-outs.
4. Portfolio cannibalization if a manufacturer offers multiple esmolol SKUs, causing channel conflict during procurement.

Key catalysts that can improve commercial outcomes

1. Faster formulary placement for the double-strength plastic-container SKU if it aligns with hospital protocol and substitution policy.
2. Improved supply reliability that secures long-term contract volume.
3. Competitive net pricing that wins GPO and tender benchmarks without sacrificing supply.

What measurable indicators should be tracked to model this product’s financial course?

For an actionable financial view in an investment or R&D commercialization context, track these indicators over time:

Indicator	Why it moves revenue or margin	What to watch
Contract net price vs. peers	IV generics face rapid price compression	Tender results and GPO benchmarks
Formulary share by hospital tier	Inpatient substitution is policy-dependent	Pharmacy committee additions/removals
Unit demand per case	Reflects protocol uptake and titration patterns	Utilization reports by specialty
Supply continuity	Prevents lost contracts and substitution delays	Backorder rates and allocation notices
SKU parity (concentration/container matching)	Direct substitution increases share gain and price pressure	Competitor SKU listings and approvals

How to frame the “double strength in plastic container” as a business unit

The product should be treated as a contracted, hospital-administered, IV generics-style SKU. Its financial trajectory will track:

• Share wins when the presentation matches hospital operational preferences and when net price beats alternative contracted SKUs.
• Share and margin loss when additional equivalent offerings enter or when contract pricing resets lower.

Key Takeaways

• The product’s demand base is acute inpatient care, with sales dominated by formularies, GPO benchmarks, and tender contracting rather than patient-driven volume.
• Its “double strength” and plastic container format influence workflow fit and can support faster formulary adoption, but they do not typically prevent generic price compression once multiple equivalent products are available.
• Financial performance is best modeled as a lifecycle curve: early stability tied to adoption, then margin compression as competitors secure contract access, with late-stage revenue becoming volume and supply reliability dependent.
• The dominant drivers of net revenue are contract net price, formulary share, and supply continuity; the dominant risks are rebid-driven price resets and substitution acceleration after new equivalent entrants.

FAQs

1. Is esmolol’s market demand stable or cyclical?
   It is primarily tied to hospital acute case mix and protocol adoption, with demand volatility typically lower than elective-care products but sensitive to supply continuity and formulary switching.

2. Does “double strength” change the competitive threat?
   It can reduce infusion volume and improve workflow fit, which supports adoption, but direct competition remains strong if peers offer equivalent concentration and container formats.

3. What determines net pricing in this segment?
   Contracting outcomes dominate: tender bids, GPO benchmarks, and hospital formulary substitution policies typically drive net price more than list price.

4. What supply events matter most financially?
   Stock-outs and manufacturing disruptions that cause lost contract volume or hospital exclusion after replenishment delays.

5. What are the most actionable KPIs for forecasting revenue?
   Contract net price, formulary share at target accounts, unit demand per case, supply continuity metrics, and competitor SKU parity (concentration and container matching).

References

[1] APA Dictionary of Psychology. American Psychological Association. https://dictionary.apa.org/
[2] FDA. Drug Approval and Safety Information. https://www.accessdata.fda.gov/scripts/cder/da/
[3] FDA Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/